Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Прижизненное донорство почки

Список литературы

  1. Данович ГМ. Трансплантация почки. М: ГЭОТАР-Медиа; 2013: 848.
  2. Федеральный закон от 21.11.2011 N 323-ФЗ (ред. от 29.05.2019) "Об основах охраны здоровья граждан в Российской Федерации". Статья 47. Донорство органов и тканей человека и их трансплантация (пересадка).
  3. Fresenius medical care annual report 2018; 2018.
  4. Андрусев АМ, Томилина НА, Перегудова НГ, Шинкарев МБ. 3аместительная терапия терминальной хронической почечной недостаточности в Российской Федерации 2014-2018 гг. Отчет по данным Общероссийского Регистра заместительной почечной терапии Российского диализного общества; 2019.
  5. Готье СВ, Хомяков СМ. Донорство и трансплантация органов в Российской Федерации в 2019 году. XII сообщение регистра Российского трансплантологического общества. Вестник трансплантологии и искусственных органов. 2020; 22(2): 8-34.
  6. Закон РФ от 22.12.1992 N 4180-1 ред. от 29.11.2007 «О трансплантации органов и (или) тканей человека».
  7. Englum BR, Schechter MA, Irish WD, et al. Outcomes in kidney transplant recipients from older living donors. Transplantation 2015; 99: 309-15.
  8. Oien CM, Reisæter AV, Leivestad T, Dekker FW, Line PD, Os I. Living donor kidney transplantation: the effects of donor age and gender on short- and longterm outcomes. Transplantation 2007; 83: 600-6.
  9. Hawley CM, Kearsley J, Campbell SB, et al. Estimated donor glomerular filtration rate is the most important donor characteristic predicting graft function in recipients of kidneys from live donors. Transpl Int 2007; 20: 64-72.
  10. KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. Transplantation. 2017; 101, N8S-1: 1–106.
  11. Thiessen C, Gordon EJ, Reese PP, et al. Development of a donor- centered approach to risk assessment: rebalancing nonmaleficence and autonomy. Am J Transplant. 2015; 15: 2314–2323.
  12. Delmonico F, Council of the Transplantation Society. A report of the Amsterdam forum on the care of the live kidney donor: data and medical guidelines. Transplantation. 2005; 79 (6 Suppl): S53–S66.
  13. British Transplantation Society / Renal Association UK Guidelines for Living Donor Kidney Transplantation 2018. https://bts.org.uk/wp-content/uploads/2018/07/FINAL_LDKT-guidelines_June-2018.pdf
  14. ОPTN (Organ Procurement and Transplantation Network)/UNOS (United Network for Organ Sharing). OPTN Policies, Policy 14: Living Donation. http://optn.transplant.hrsa.gov/governance/policies/. (Accessed: June 28, 2017).
  15. Cancer Research UK: Cancer Incidence by Age: 2012-2014. http://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence/age - heading-Zero.
  16. Fehrman-Ekholm I, Gabel H, Magnusson G. Reasons for not accepting living kidney donors. Transplantation 1996; 61: 1264-5.
  17. Young A, Karpinski M, Treleaven D, et al. Differences in tolerance for health risk to the living donor among potential donors, recipients, and transplant professionals. Kidney Int 2008; 73: 1159-66.
  18. International Diabetes Federation: Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. World Health Organisation (WHO); 2006.
  19. Tydén G, Kumlien G, Berg UB. ABO-incompatible kidney transplantation in children. Pediatr Transplant. 2011; 15(5): 502-4.
  20. Hourmant M, Figueres L, Gicquel A, et al. New rules of ABO-compatibility in kidney transplantation. Transfus Clin Biol. 2019; 26(3): 180-183.
  21. Shaw C, Sharp CC. Could sickle cell trait be a predisposing risk factor for CKD? Nephrol Dial Transplant 2010; 25: 2403-5.
  22. RP Naik, VK Derebail, ME Grams, et al. Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans. JAMA 2014; 312: 2115-25.
  23. Reese PP, Hoo AC, Magee CC. Screening for sickle trait among potential live kidney donors: policies and practices in US transplant centers. Transpl Int 2008; 21: 328-31.
  24. Cetin T, Oktenli C, Ozgurtas T, et al. Renal tubular dysfunction in betathalassemia minor. Am J Kidney Dis 2003; 42: 1164-8.
  25. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). Флебология, 2015; 9 (2): 4-46.
  26. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e326-50.
  27. Fenton A., Montgomery E.,  Nightingale P., Peters A.M., Sheerin N., Wroe A.C.,  Lipkin G.W. Glomerular filtration rate: new age- and gender- specific reference ranges and thresholds for living kidney donation. BMC Nephrol. 2018; 19: 336. doi: 10.1186/s12882-018-1126-8.
  28. Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int 2003; 63: 1468-74.
  29. Halbesma N, Kuiken DS, Brantsma AH, et al. Macroalbuminuria is a better risk marker than low estimated GFR to identify individuals at risk for accelerated GFR loss in population screening. J Am Soc Nephrol 2006; 17: 2582-90.
  30. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of healthcare-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36: 309-32.
  31. Wise GJ, Schlegel PN. Sterile pyuria. N Engl J Med 2015; 372: 1048-54.
  32. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-81.
  33. AUA Guidelines 2020: Microhematuria. https://www.urotoday.com/conference-highlights/aua-2020/aua-2020-bladder-health/122536-aua-guidelines-2020-microhematuria.html
  34. Mohr DN, Offord KP, Owen RA, Melton LJ. Asymptomatic microhematuria andurologic disease: a population based study. JAMA 1986; 256: 224-9.
  35. Vivante A, Afek A, Frenkel-Nir Y, et al. Persistent asymptomatic isolated microscopic hematuria in Israeli adolescents and young adults and risk for endstage renal disease. JAMA 2011; 306: 729-36.
  36. Yamagata K, Kobayashi M, Koyama A. A long-term follow up study of asymptomatic haematuria and/or proteinuria in adults. Clin Nephrol 1996; 45: 281-8.
  37. Jaffe JS, Ginsberg PC, Gill R, Harkaway RC. A new diagnostic algorithm for the evaluation of microscopic haematuria. Urology 2001; 57: 889-94.
  38. Koushik R, Garvey C, Manivel C, Matas AJ, Kasiske B. Persistent, asymptomatic microscopic hematuria in prospective kidney donors. Transplantation 2005; 80: 1425-9.
  39. Khadra MH, Pickard RS, Charlton M, Powell PH, Neal DE. A prospective analysis of 1,930 patients with haematuria to evaluate current diagnostic practice. J Urol 2000; 163: 524-7.
  40. Edwards TJ, Dickinson AJ, Natale S, Gosling J, McGrath JS. A prospective analysis of the diagnostic yield resulting from the attendance of 4020 patients at a protocol-driven haematuria clinic. BJU Int 2006; 97: 301-5.
  41. Постановление Правительства РФ от 22.06.2019 N 797 «Об утверждении Правил заготовки, хранения, транспортировки и клинического использования донорской крови и ее компонентов и о признании утратившими силу некоторых актов Правительства Российской Федерации».
  42. Guidance on microbiological safety of human organs, tissues and cells used in transplantation. Advisory Committee on the Safety of Blood Tissues and Organs (SaBTO); 2018.
  43. Van Son WJ, The TH. Cytomegalovirus infection after organ transplantation: an update with special emphasis on renal transplantation. Transpl Int 1989; 2: 147-64.
  44. Cook RI, Wreathall J, Smith A, et al. Probabilistic risk assessment of accidental ABO-incompatible thoracic organ transplantation before and after 2003. Transplantation. 2007; 84: 1602–1609.
  45. Montgomery JR, Berger JC, Warren DS, et al. Outcomes of ABO- incompatible kidney transplantation in the United States. Transplantation. 2012; 93: 603–609.
  46. Tait BD, Süsal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA an- tibodies in transplantation. Transplantation. 2013; 95(1): 19-47.
  47. Lobashevsky AL, Higgins NG, Rosner Kevin M, et al. Analysis of anti-HLA antibodies in sensitized kidney transplant candidates subjected to desensitization with intravenous immunoglobulin and rituximab. Transplantation. 2013; 96(2): 182-90.
  48. Taylor CJ, Kosmoliaptsis V, Summers DM, Bradley JA. Back to the future: application of contemporary technology to longstanding questions about the clinical relevance of human leukocyte antigen-specific alloantibodies in renal transplantation. Human Immunol 2009; 70: 563-8.
  49. Opelz G. Impact of HLA compatibility on survival of kidney transplants from unrelated live donors. Transplantation 1997; 64: 1473-5.
  50. Terasaki PI, Cecka JM, Gjertson DW, Cho YW. Spousal and other living donor transplants. Clinical Transplants, 1997; 01 Jan 1997: 269-84.
  51. Collaborative Transplant Study Newsletter. Heidelberg University Institute of Immunology; 2004.
  52. Fuggle SV, Allen JE, Johnson RJ, et al. Factors affecting graft and patient survival after live donor kidney transplantation in the UK. Transplantation 2010; 89: 694-701.
  53. Gloor JM, Lager DJ, Moore SB, et al. ABO-incompatible kidney trans- plantation using both A2 and non-A2 living donors. Transplantation. 2003; 75: 971–977.
  54. Bachelet T, Martinez C, Del Bello A, et al. Deleterious impact of donor- specific anti-HLA antibodies toward HLA-Cw and HLA-DP in kidney transplantation. Transplantation. 2016; 100: 159–166.
  55. Filippone EJ, Farber JL. Humoral immune response and allograft function in kidney transplantation. Am J Kidney Dis. 2015; 66: 337–347.
  56. Maron BJ, Shirani J, Poliac LC, et al. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA 1996; 276: 199-204.
  57. Habbous S, Arnold J, Begen MA, et al. Duration of Living Kidney Transplant Donor Evaluations: Findings From 2 Multicenter Cohort Studies. Am J Kidney Dis. 2018; 72(4): 483-498.
  58. Kim IK, Tan JC, Lapasia J, et al. Incidental kidney stones: a single center experience with kidney donor selection. Clin Transplant. 2012; 26(4): 558-63.
  59. Strang AM, Lockhart ME, Amling CL, et al. Living renal donor allograft lithiasis: a review of stone related morbidity in donors and recipients. J Urol. 2008; 179(3): 832-6.
  60. Rizkala E, Coleman S, Tran C, et al. Stone disease in living-related renal donors: long-term outcomes for transplant donors and recipients. J Endourol. 2013; 27(12): 1520-4.
  61. Tan N, Charoensak A, Ajwichai K, et al. Prevalence of incidental findings on abdominal computed tomography angiograms on prospective renal donors. Transplantation 2015; 99: 1203-7.
  62. Maizlin Z, Barnard SA, Gourlay WA, Brown JA. Economic and ethical impact of extrarenal findings on potential living kidney donor assessment with computed tomography angiography. Transpl Int 2007; 20: 338-42.
  63. BTS/RA Guidelines for living donor kidney transplantation. 4th edition; 2018.
  64. Obrador G, et al. The consensus statement of the Amsterdam Forum on the care of the live kidney donor transplantation. Transplantation. 2004; 78(4): 491-2.
  65. Костюченко МВ. Современные методы профилактики тромбоэмболических осложнений в послеоперационном периоде. Consilium Medicum. 2019; 21 (8): 102–107.
  66. NICE Guidance on VTE. www.nice.org.uk/guidance/CG92.
  67. Kakkar AK. Prevention of venous thromboembolism in general surgery. In: Colman RW, Clowes AW, George JN, Goldhaber SZ, Marder VJ,eds. Hemostasis and thrombosis: basic principles and clinical practice. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2006: 1361-7.
  68. Хирургические инфекции кожи и мягких тканей: Российские национальные рекомендации для врачей. М.: Боргес; 2009: 89.
  69. Dellinger EP, Gross PA, Barrett TL, et al. Quality standart for antimicrobial prophylaxis in surgical procedures. Clin Infect Dis 1994; 18: 422-7.
  70. Bratzler DW, et al. Antibiotic prophylaxis for surgery: An advisory statement from the National Surgical Infection. Prevention Project. Clin Infect Dis 2004; 38:1706.
  71. Orlando G, et al. One-shot versus multidose perioperative antibiotic prophylaxis after kidney transplantation: a randomized, controlled clinical trial. Surgery, 2015; 157: 104.
  72. Choi SU, et al. Clinical significance of prophylactic antibiotics in renal transplantation. Transplant Proc, 2013; 45: 1392.
  73. Chowdhury AH, Cox EF, Francis ST, Lobo DN. A randomized, controlled, double-blind crossover study on the effects of 2-L infusions of 0.9% saline and plasma-lyte(R) 148 on renal blood flow velocity and renal cortical tissue perfusion in healthy volunteers. Ann Surg 2012; 256: 18-24.
  74. Shaw AD, Bagshaw SM, Goldstein SL, et al. Major complications, mortality, and resource utilization after open abdominal surgery. Ann Surg 2012; 255: 821-9.
  75. Varadhan KK, Lobo DN. A meta-analysis of randomised controlled trials of intravenous fluid therapy in major elective open abdominal surgery: getting the balance right corrigendum. Proc Nutr Soc 2010; 69: 488-98.
  76. Lennerling A, et al. Living organ donation practices in Europe - results from an online survey. Transpl Int, 2013; 26: 145.
  77. Antcliffe D, et al. A meta-analysis of mini-open versus standard open and laparoscopic living donor nephrectomy. Transpl Int, 2009; 22: 463.
  78. Greco F, et al. Laparoscopic living-donor nephrectomy: analysis of the existing literature. Eur Urol, 2010; 58: 498.
  79. Wilson CH, et al. Laparoscopic versus open nephrectomy for live kidney donors. Cochrane Database Syst Rev; 2011.
  80. Yuan H, et al. The safety and efficacy of laparoscopic donor nephrectomy for renal transplantation: an updated meta-analysis. Transplant Proc, 2013; 45: 65.
  81. Dols LF, Kok NF, Ijzermans JN. Live donor nephrectomy: a review of evidence for surgical techniques. Transplant Int 2010; 23: 121-30.
  82. Breda A., et al. Mini-laparoscopic live donor nephrectomy with the use of 3-mm instruments and laparoscope. World J Urol, 2015; 33: 707.
  83. Giacomoni A, et al. Robotic nephrectomy for living donation: surgical technique and literature systematic review. Am J Surg, 2016; 211: 1135.
  84. Lentine KL, et al. Perioperative Complications After Living Kidney Donation: A National Study. Am J Transplant, 2016; 16: 1848.
  85. Autorino R, et al. Laparoendoscopic single-site (LESS) vs laparoscopic living-donor nephrectomy: a systematic review and meta-analysis. BJU Int, 2015; 115: 206.
  86. Alcaraz A, et al. Feasibility of transvaginal natural orifice transluminal endoscopic surgery-assisted living donor nephrectomy: is kidney vaginal delivery the approach of the future? Eur Urol, 2011; 59: 1019.
  87. Hsu TH, Su LM, Ratner LE, et al. Impact of renal artery multiplicity on outcomes of renal donors and recipients in laparoscopic donor nephrectomy. Urology 2003; 61: 323-7.
  88. Chedid ME, Muthu C, Nyberg SL, et al. Living donor kidney transplantation using laparoscopically procured multiple renal artery kidneys and right kidneys. J Am Coll Surg 2013; 217: 144-52.
  89. Boudville N, Prasad GV, Knoll G, et al. Meta-analysis: risk for hypertension in living kidney donors. Ann Intern Med. 2006; 145: 185–196.
  90. Doshi MD, Goggins MO, Li L, et al. Medical outcomes in African American live kidney donors: a matched cohort study. Am J Transplant. 2013; 13: 111–118.
  91. Jones JW, Acton RD, Elick B, et al. Pregnancy following kidney donation. Transplant Proc 1993; 25: 3082.
  92. Buszta C, Steinmuller DR, Novick AC, et al. Pregnancy after donor nephrectomy. Transplantation 1985; 40: 651-4.
  93. Reisaeter AV, Roislien, J, Henriksen, et al. Pregnancy and birth after kidney donation: the Norwegian experience. Am J Transplant 2009; 9: 820-4.
  94. Ibrahim HN, Akkina SK, Leister E, et al. Pregnancy outcomes after kidney donation. Am J Transplant 2009; 9: 825-34.
  95. Garg AX, Nevis IF, McArthur E, et al. Gestational hypertension and preeclampsia in living kidney donors. N Engl J Med 2015; 372: 124-33.
  96. National Institute of Clinical and Health Excellence: Hypertension in pregnancy: the management of hypertensive disorders during pregnancy; 2010.
  97. Mol BW, Roberts CT, Thangaratinam S, et al. Pre-eclampsia. Lancet 2015; 387: 999-1011.
  98. Living Donor Registry. https://www.nhsbt.nhs.uk/
  99. Fehrman-Ekholm I, Elinder CG, Stenbeck M, et al. Kidney donors live longer. Transplantation 1997; 64: 976-8.
  100. Fehrman-Ekholm I, Norden G, Lennerling A, et al. Incidence of end stage renal disease among live kidney donors. Transplantation 2006; 82: 1646-8.
  101. Najarian JS, Chavers BM, McHugh LE, Matas AJ. 20 years or more of followup of living kidney donors. Lancet 1992; 340: 807-10.
  102. Ibrahim HN, Foley R, Tan L, et al. Long-term consequences of kidney donation. N Engl J Med 2009; 360: 459-69.
  103. Segev DL, Muzaale AD, Caffo BS, et al. Perioperative mortality and long-term survival following live kidney donation. JAMA 2010; 303: 959-66.
  104. Muzaale AD, Massie A, Wang MC, et al. Risk of end-stage renal disease following live kidney donation. JAMA 2014; 311: 579-86.
  105. Mjoen G, Hallan S, Hartmann A, et al. Long-term risks for kidney donors. Kidney Int 2014; 86: 162-7.
  106. Leichtman A, Abecassis M, Barr M, et al. Living kidney donor follow-up: state-of-the-art and future directions, conference summary and recom- mendations. Am J Transplant. 2011; 11: 2561–2568.
  107. Van Assche K, Sterckx S, Lennerling A, et al. The relevance of Directive 2010/53/EU for living organ donation practice: an ELPAT view. Transplantation. 2015; 99: 2215–2222.
  108. Procedures to collect post- donation follow-up data from living donors. OPTN/UNOS Living Donor Committee; 2015.
  109. Kortram K, et al. Perioperative Events and Complications in Minimally Invasive Live Donor Nephrectomy: A Systematic Review and Meta-Analysis. Transplantation 2016; 100(11): 2264-2275.
  110. Segev DL., et al. Perioperative mortality and long-term survival following live kidney donation. JAMA, 2010; 303: 959.
  111. Chu KH., et al. Long-term outcomes of living kidney donors: a single centre experience of 29 years. Nephrology (Carlton), 2012; 17: 85.
  112. Fehrman-Ekholm I, et al. Post-nephrectomy development of renal function in living kidney donors: a cross-sectional retrospective study. Nephrol Dial Transplant, 2011; 26: 2377.
  113. Ibrahim HN, et al. Long-term consequences of kidney donation. N Engl J Med, 2009; 360: 459.
  114. Li SS, et al. A meta-analysis of renal outcomes in living kidney donors. Medicine (Baltimore), 2016; 95: e3847.
  115. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020 Oct;98(4S):S1-S115. doi: 10.1016/j.kint.2020.06.019. PMID: 32998798.
  116. Lentine K.L., Kasiske B.L., Levey A.S. et al. KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. Transplantation. 2017 Aug;101(8S Suppl 1):S1-S109. doi: 10.1097/TP.0000000000001769.
  117. Tong A, Chapman JR, Wong G, et al. Screening and follow-up of living kidney donors: a systematic review of clinical practice guidelines. Transplantation. 2011;92:962–972.
  118. Tong A, Chapman JR, Wong G, et al. Living kidney donor assessment: challenges, uncertainties and controversies among transplant nephrologists and surgeons. Am J Transplant. 2013;13:2912–2923.
  119. Grams ME, Sang Y, Levey AS, et al. Kidney-failure risk projection for the living kidney-donor candidate. N Engl J Med. 2016;374:411–421.
  120. Huang N, Foster MC, Lentine KL, et al. Estimated GFR for living kidney donor evaluation. Am J Transplant. 2016;16:171–180
  121. Anjum S, Muzaale AD, Massie AB, et al. Patterns of end-stage renal disease caused by diabetes, hypertension, and glomerulonephritis in live kidney donors. Am J Transplant. 2016;16: 3540–3547.
  122. . Monaco A. P., Morris P. J. Care of the live kidney donor: consensus on the ultimate gift //Transplantation-Baltimore. – 2005. – Т. 79. – №. 6. – С. S51.
  123. . Sawinski D., Locke J. E. Evaluation of kidney donors: core curriculum 2018 //American Journal of Kidney Diseases. – 2018. – Т. 71. – №. 5. – С. 737-747.
  124. Davis C. L., Delmonico F. L. Living-donor kidney transplantation: a review of the current practices for the live donor //Journal of the American Society of Nephrology. – 2005. – Т. 16. – №. 7. – С. 2098-2110.
  125. Kasiske B. L., Bia M. J. The evaluation and selection of living kidney donors //American journal of kidney diseases. – 1995. – Т. 26. – №. 2. – С. 387-398.
  126. Caliskan Y., Yildiz A. Evaluation of the medically complex living kidney donor //Journal of transplantation. – 2012. – Т. 2012
  127. Montgomery R. A. et al. Desensitization in HLA-incompatible kidney recipients and survival //New England Journal of Medicine. – 2011. – Т. 365. – №. 4. – С. 318-326.
  128. Weinberger S. et al. Optimizing scintigraphic evaluation of split renal function in living kidney donors using the geometric mean method: a preliminary retrospective study //Journal of Nephrology. – 2016. – Т. 29. – №. 3. – С. 435-441.
  129. Weinberger S. et al. Influence of CT-based depth correction of renal scintigraphy in evaluation of living kidney donors on side selection and postoperative renal function: is it necessary to know the relative renal function? //World Journal of Urology. – 2018. – Т. 36. – №. 8. – С. 1327-1332.
  130. Pippias M. et al. Pregnancy after living kidney donation, a systematic review of the available evidence, and a review of the current guidance //American Journal of Transplantation. – 2022.
  131. S. Halvorsen, J. Mehilli, S. Cassese et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery: Developed by the task force for cardiovascular assessment and management of patients undergoing non-cardiac surgery of the European Society of Cardiology (ESC) Endorsed by the European Society of Anaesthesiology and Intensive Care (ESAIC) // European Heart Journal, 2022. – Vol. 43, Iss. 39, P. 3826–3924. https://doi.org/10.1093/eurheartj/ehac270

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*